Verdad Advisers’s Solid Biosciences SLDB Stock Holding History

Verdad Advisers’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,879	Closed	-$107K	–	266
2026 Q1	$107K	Buy	+14,879	New	+$95.6K	0.12%	152

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Verdad Advisers's SLDB Position: Q2 2026 in Review

Verdad Advisers sold out of Solid Biosciences (SLDB) in Q2 2026, closing a stake of 14,879 shares — an estimated $107K sold.

Verdad Advisers first reported a position in SLDB in Q1 2026 and held it in 1 quarter. The position peaked at $107K in Q1 2026. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Verdad Advisers reported no remaining Solid Biosciences position as of Q2 2026 after selling out during the quarter.
Verdad Advisers sold 14,879 Solid Biosciences shares in Q2 2026, an estimated $107K.
Verdad Advisers first reported a position in Solid Biosciences in Q1 2026 and held it in 1 quarter.
Verdad Advisers's Solid Biosciences position peaked at $107K in Q1 2026.
156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.